Evidence map›Paper›PMID 29169317›Full record

ArticleBMC bioinformatics2017

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data.

Marco Beccuti, Elisa Genuardi, Greta Romano, Luigia Monitillo, Daniela Barbero, Mario Boccadoro, Marco Ladetto, Raffaele Calogero, Simone Ferrero, Francesca Cordero

Open access · goldAbstract read
In one paragraph

Article in BMC bioinformatics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. [Latest advances in minimal residual disease evaluation in B-cell lymphoproliferative disease].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Marco BeccutiDepartment of Computer Science, University of Torino, Via Pesinetto 12, Turin, 10149, Italy.
Elisa GenuardiDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Via Genova 3, Turin, 10126, Italy.
Greta RomanoDepartment of Computer Science, University of Torino, Via Pesinetto 12, Turin, 10149, Italy.
Luigia MonitilloDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Via Genova 3, Turin, 10126, Italy.
Daniela BarberoDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Via Genova 3, Turin, 10126, Italy.
Mario BoccadoroDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Via Genova 3, Turin, 10126, Italy.
Marco LadettoDivision of Hematology, Az. Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Via Venezia 16, Alessandria, 15121, Italy.
Raffaele CalogeroDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, Turin, 10125, Italy.
Simone FerreroDivision of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Via Genova 3, Turin, 10126, Italy.
Francesca CorderoDepartment of Computer Science, University of Torino, Via Pesinetto 12, Turin, 10149, Italy. fcordero@di.unito.it.ORCID http://orcid.org/0000-0002-3143-3330
University of Turin · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · IT

Funding

Fondazione Cassa di Risparmio di Torino 2015.1044PRIN2009 7.07.02.60 AE01Progetto di Ricerca Sanitaria Finalizzata 2009 RF-2009-1469205Progetto di Ricerca Sanitaria Finalizzata 2010 RF-2010-2307262
6 · The paper itself

Abstract

backgroundMantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in other B lymphoproliferative disorders, is the ImmunoGlobulin Heavy chain (IGH) rearrangement, occurring in B-lymphocytes. The patient-specific IGH rearrangement is extensively used to monitor the Minimal Residual Disease (MRD) after treatment through the standardized Allele-Specific Oligonucleotides Quantitative Polymerase Chain Reaction based technique. Recently, several studies have suggested that the IGH monitoring through deep sequencing techniques can produce not only comparable results to Polymerase Chain Reaction-based methods, but also might overcome the classical technique in terms of feasibility and sensitivity. However, no standard bioinformatics tool is available at the moment for data analysis in this context.

resultsIn this paper we present HashClone, an easy-to-use and reliable bioinformatics tool that provides B-cells clonality assessment and MRD monitoring over time analyzing data from Next-Generation Sequencing (NGS) technique. The HashClone strategy-based is composed of three steps: the first and second steps implement an alignment-free prediction method that identifies a set of putative clones belonging to the repertoire of the patient under study. In the third step the IGH variable region, diversity region, and joining region identification is obtained by the alignment of rearrangements with respect to the international ImMunoGenetics information system database. Moreover, a provided graphical user interface for HashClone execution and clonality visualization over time facilitate the tool use and the results interpretation. The HashClone performance was tested on the NGS data derived from MCL patients to assess the major B-cell clone in the diagnostic samples and to monitor the MRD in the real and artificial follow up samples.

conclusionsOur experiments show that in all the experimental settings, HashClone was able to correctly detect the major B-cell clones and to precisely follow them in several samples showing better accuracy than the state-of-art tool.

Indexed as

AlgorithmsAllelesB-LymphocytesClone CellsHumansLymphoma, B-CellNeoplasm, ResidualReproducibility of ResultsClonality assessmentHash-based algorithmMinimal residual disease monitoring

Identifiers

PMID29169317
PMCPMC5701356
OpenAlexW2770481585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.